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Arenaviruses cause severe human disease ranging from aseptic meningitis following lymphocytic chorio-
meningitis virus (LCMV) infection to hemorrhagic fever syndromes following infection with Guanarito virus
(GTOV), Junin virus (JUNV), Lassa virus (LASV), Machupo virus (MACV), Sabia virus (SABV), or White-
water Arroyo virus (WWAV). Cellular immunity, chiefly the CD8 T-cell response, plays a critical role in
providing protective immunity following infection with the Old World arenaviruses LASV and LCMV. In the
current study, we evaluated whether HLA class I-restricted epitopes that are cross-reactive among pathogenic
arenaviruses could be identified for the purpose of developing an epitope-based vaccination approach that
would cross-protect against multiple arenaviruses. We were able to identify a panel of HLA-A*0201-restricted
peptides derived from the same region of the glycoprotein precursor (GPC) of LASV (GPC spanning residues
441 to 449 [GPC441-449]), LCMV (GPC447-455), JUNV (GPC429-437), MACV (GPC444-452), GTOV (GPC427-435),
and WWAV (GPC428-436) that displayed high-affinity binding to HLA-A*0201 and were recognized by CD8
 T
cells in a cross-reactive manner following LCMV infection or peptide immunization of HLA-A*0201 transgenic
mice. Immunization of HLA-A*0201 mice with the Old World peptide LASV GPC441-449 or LCMV GPC447-455
induced high-avidity CD8 T-cell responses that were able to kill syngeneic target cells pulsed with either
LASV GPC441-449 or LCMV GPC447-455 in vivo and provided significant protection against viral challenge with
LCMV. Through this study, we have demonstrated that HLA class I-restricted, cross-reactive epitopes exist
among diverse arenaviruses and that individual epitopes can be utilized as effective vaccine determinants for
multiple pathogenic arenaviruses.
Arenaviruses are a family of rodent-borne viruses that are
associated with severe disease in humans. Phylogenetically, the
arenaviruses are organized into Old World or New World
groups, with a subdivision of the New World viruses falling into
three distinct lineages (A to C) (17). At least eight arenaviruses
are known to cause human disease. Of the New World viruses,
Junin virus (JUNV), Machupo virus (MACV), Guanarito virus
(GTOV), and Sabia virus (SABV) (all members of lineage B)
are etiologic agents of hemorrhagic fever syndromes in South
America, while Whitewater Arroyo virus (WWAV) (lineage
A) has been linked to two fatalities in North America (13, 17).
Lassa virus (LASV), Lujo virus, and lymphocytic choriomen-
ingitis virus (LCMV) represent the Old World viruses that
cause disease in humans (10, 13). LASV and Lujo virus, both
of which are found in Africa, can cause hemorrhagic fevers,
while LCMV infection, which is endemic throughout the
world, can result in aseptic meningitis in immunocompetent
individuals (10, 15, 33). LCMV is also a potent teratogen
responsible for outcomes such as hydrocephaly and chorioreti-
nitis in developing fetuses (3–5, 31, 36) or high lethality in
immunosuppressed patients (20). LASV, LCMV, JUNV,
GTOV, and MACV are NIAID category A agents, and with
the exception of LCMV, each of these viruses is also on the
CDC select agent list of potential bioterrorism threat agents.
At present, vaccines for the prevention of human arenavirus
disease are limited to a single live attenuated vaccine (Candid
1) for the prevention of JUNV infection. JUNV Candid 1,
which is classified as an investigational new drug in the United
States, was derived from the wild-type (WT) JUNV strain
XJ13 through serial passage both in vivo and in vitro (22). The
only antiviral agent currently utilized for treatment of a subset
of arenavirus infections is ribavirin (23, 35). Passive antibody
therapy has been effective in reducing mortality associated with
Argentine hemorrhagic fever caused by infection with JUNV
(19, 32).
Arenaviruses have an RNA genome that is encoded in an
ambisense fashion and consists of two single-stranded RNA
segments, the 3-kb small (S) segment and 7-kb large (L)
segment. The arenavirus proteome consists of four proteins:
the viral RNA-dependent RNA polymerase (L) and zinc bind-
ing protein, which are encoded on the L segment, and the S
segment-encoded nucleoprotein (NP) and glycoprotein pre-
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cursor (GPC), which is posttranslationally modified to yield a
stable signal peptide, GP1, and GP2 (49). GP1 and GP2 form
heterodimers that facilitate entry into permissive host cells
through an interaction with either -dystroglycan for the Old
World viruses LASV and LCMV (i.e., for strain clone 13 but
not strain Armstrong 53b) (16, 30) or transferrin receptor 1 for
a subset of the pathogenic New World arenaviruses (1, 41, 42).
GP1 is also the target of antiviral neutralizing antibodies
(nAbs) (11). The NP and L protein, which are encoded in
negative or antimessage sense, are the first proteins to be
expressed following infection, whereas the GPC and zinc bind-
ing protein, which are encoded in positive or message sense,
arise later, demonstrating the temporal control of gene expres-
sion that is inherent in arenavirus replication.
The cellular immune response, specifically the CD8 T-cell
response, is important for the development of protective im-
munity following arenavirus infection (for a review, see refer-
ence 9). This is particularly true for the pathogenic Old World
arenaviruses LCMV and LASV, as high-quality antiviral nAbs
typically do not form following infection with these viruses;
low-titer nAbs, if formed, usually appear weeks to months
following clearance of the primary infection (11, 14, 18, 21, 34).
In the case of LCMV, it was recently shown that the GPC
itself, not the viral backbone, is responsible for this poor nAb
response (40). This observation has important implications for
vaccine design, as delivery of Old World arenavirus GPCs in
even the most immunogenic of vectors may not improve the
kinetics or magnitude of nAb formation following immuniza-
tion. Therefore, vaccine development strategies for Old World
arenaviruses must necessarily focus on the induction of pro-
tective cellular immune responses. In contrast, New World
arenaviruses such as JUNV and MACV are able to induce
both high-quality cellular and humoral immune responses fol-
lowing infection (39).
A significant challenge currently facing vaccine development
is pathogen heterogeneity. In the case of arenaviruses, the low
incidence of disease observed for the majority of these anti-
genically diverse viruses combined with the low socioeconomic
status of the countries where they are endemic makes it un-
likely that individual vaccines will be developed for each of the
eight pathogenic arenaviruses. Therefore, the development of
multivalent vaccines capable of providing cross-protection
against multiple pathogenic arenavirus family members is de-
sirable. It has been well-established that CD8 T-cell epitopes
are effective vaccine determinants for arenaviruses (6, 8, 25, 29,
43, 44) and that cross-protective cellular immune responses are
generated following arenavirus infection in animal models (39,
43). In the current study, we evaluated whether HLA class
I-restricted epitopes that are cross-reactive among pathogenic
arenavirus species could be identified for the purpose of de-
veloping an epitope-based, multivalent vaccination approach
that would cross-protect against multiple arenaviruses.
MATERIALS AND METHODS
Amino acid sequence analyses. The arenavirus open reading frames utilized in
this study were those encoding LASV strain Josiah GPC (NCBI accession num-
ber NP_694870), LCMV strain Armstrong 53b GPC (NCBI accession number
NP_694851), MACV strain Carvallo GPC (NCBI accession number AAN05425),
JUNV strain MC2 GPC (NCBI accession number BAA00964), GTOV strain
INH-95551 GPC (NCBI accession number AAN05423), SABV strain
SPH114202 GPC (NCBI accession number AAC55091), WWAV strain
AV9310135 GPC (NCBI accession number AAK60497), and Pichinde virus
(PICV) strain Munchique GPC (NCBI accession number AAC32281).
Peptides. Peptides (90% pure) were obtained from Genemed Synthesis, Inc.
(South San Francisco, CA). Each peptide was purified by high-performance
liquid chromatography (HPLC), and the sequence was verified by mass spec-
trometry. Hepatitis B virus (HBV) ENV 378 (LLPIFFCLWV) was used as an
irrelevant, HLA-A*0201-restricted peptide.
MHC-peptide binding assays. Major histocompatibility complex (MHC) mol-
ecules were purified and binding assays were performed, as previously described
(47, 48). Briefly, 1 to 10 nM radiolabeled peptide was coincubated with 1 M to
1 nM purified MHC in the presence of 1 to 3 M human 2-microglubulin. After
2 days, binding of the radiolabeled peptide to the corresponding MHC class I
molecule was determined by capturing MHC-peptide complexes on Greiner
Lumitrac 600 microplates (Greiner Bio-One, Longwood, FL) coated with the
W6/32 antibody and measuring bound counts per minute using a TopCount
microscintillation counter (Packard Instrument Co.).
Mice. HLA-A*0201/Kb (referred to as HLA-A*0201 throughout) transgenic
mice were bred at The Scripps Research Institute (TSRI). These mice represent
the F1 generation, resulting from a cross between HLA-A*0201/Kb transgenic
mice (that express a chimeric gene consisting of the 1 and 2 domains of
HLA-A*0201 and the 3 domain of H-2Kb) created on the C57BL/6 background
and BALB/c mice (The Jackson Laboratory) (53). All studies were conducted in
facilities approved by the Association for Assessment and Accreditation of Lab-
oratory Animal Care and according to Institutional Animal Care and Use Com-
mittee-approved animal protocols.
Cells. JA2.1 cells (human Jurkat cells that express the HLA-A*0201/Kb chi-
meric gene) (53) were grown as previously described (46).
Viruses. LCMV infections were conducted using strain Armstrong 53b. This
virus was expanded in BHK-21 cells, and the titers of the virus were determined
on Vero E6 cells. vvLASV-GPC and vvLCMV-GPC (which express LASV strain
Josiah GPC and LCMV Armstrong 53b GPC, respectively) are recombinant
vaccinia viruses (rVV) that were generated on the Western Reserve (WR)
background as previously described (6, 54).
Immunizations and viral challenges. To evaluate peptide immunogenicity,
CD8 T-cell avidity, endogenous processing of peptides from native LASV or
LCMV antigens, or in vivo cytotoxic T-lymphocyte (CTL) killing, HLA-A*0201
mice (8 to 14 weeks old) were inoculated subcutaneously (s.c.) at the base of the
tail with a mixture of CD8 T-cell peptides (50 g of each peptide per mouse)
and the helper T-cell peptides human lambda repressor 12 (YLEDARRLKAI
YEKKK), chicken ovalbumin 323 (ISQAVHAAHAEINE), and HBV core 128
(TPPAYRPPNAPIL) (46.7 g of each peptide per mouse) that had been emul-
sified 1:1 in incomplete Freund adjuvant (IFA). For intraperitoneal (i.p.) chal-
lenge studies, mice were immunized with peptide-IFA emulsions and challenged
at 14 days postimmunization via i.p. inoculation with 2  105 PFU of LCMV. At
4 days postchallenge, spleens were harvested for CD8 T-cell purification and
LCMV titer determination. To determine viral titer, a portion of each spleen was
homogenized and serial 10-fold dilutions of these homogenates were plated on
Vero E6 cells and overlaid with 1.4% agarose-Dulbecco modified Eagle medium.
Cells were fixed, and plaques were counted at 4 days postinoculation.
ELISPOT assay. Enzyme-linked immunospot (ELISPOT) assays were per-
formed as previously described (50). Briefly, 4  105 splenic CD8 T cells
(isolated by anti-CD8-coated magnetic beads [Miltenyi Biotec, Auburn, CA])
were cultured with 1  105 peptide-pulsed or rVV-infected JA2.1 target cells.
Target cells were pulsed by incubating them with peptide for at least 2 h at room
temperature, followed by three washes to remove free peptide. For rVV infec-
tions, JA2.1 cells were infected (multiplicity of infection of 10) 18 h prior to the
assay. Effector and target cells were incubated in flat-bottom 96-well nitrocellu-
lose plates (Immobilon-P membrane; Millipore) precoated with 50 l/well of
anti-gamma interferon (anti-IFN-) monoclonal antibody (MAb) (10 g/ml
Mabtech AN18). After 16 to 20 h, plates were washed and wells were incubated
with 100 l biotinylated anti-IFN- MAb (1 g/ml Mabtech R4-6A2) for 2 h.
After additional washing, spots were developed by sequential incubation with
Vectastain ABC peroxidase (Vector Laboratories) and 3-amino-9-ethyl carba-
zole solution (Sigma-Aldrich) and counted by computer-assisted image analysis
(Zeiss KS ELISPOT reader).
Each assay was performed in 3 replicate wells, and the experimental values
were expressed as the mean spots/106 CD8 T cells  standard deviations (SD)
for each peptide. Responses of CD8 T cells derived from peptide-immunized
mice against JA2.1 cells pulsed with irrelevant peptide (HBV ENV 378) or
infected with irrelevant VV constructs were measured to establish background
values.
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In vivo cytotoxicity assay. Splenocytes from HLA-A*0201 mice were labeled
with 0.3 M or 0.06 M CFSE (5,6-carboxy-fluorescein diacetate succinimidyl
ester; Molecular Probes). CFSEhi cells were pulsed with 1 g/ml of LASV GPC
spanning positions 441 to 449 (GPC441-449), LCMV GPC447-455, MACV GPC444-452/
JUNV GPC429-437, GTOV GPC427-435, or WWAV GPC428-436, while CFSElo
cells were pulsed with 1 g/ml of the irrelevant peptide HBV ENV 378. Follow-
ing extensive washing, equal numbers of CFSEhi and CFSElo cells were mixed
and delivered (8  106 total cells per mouse) via intravenous (i.v.) injection to
syngeneic HLA-A*0201 mice that had been (i) immunized 10 days earlier either
with peptide or adjuvant alone or (ii) infected via i.p. inoculation with 2  105
PFU of LCMV Armstrong 53b or were naïve. After 18 h, CFSE-labeled cells
were identified from the spleens of recipient mice by flow cytometry. The percent
killing was determined as follows: 100 	{[(% of immunizing peptide-pulsed cells
in peptide-immunized or LCMV-infected mice/% of irrelevant peptide-pulsed
cells in peptide-immunized or LCMV-infected mice)/(% of immunizing peptide-
pulsed cells in adjuvant-immunized or naïve mice/% of irrelevant peptide-pulsed
cells in adjuvant-immunized or naïve mice)]  100}. Cell staining was analyzed
by flow cytometry at the TSRI core facility by using a BD Biosciences FACS-
Calibur flow cytometer and CellQuest software.
Statistical analyses. To evaluate whether a CD8 T-cell response to peptide-
pulsed or rVV-infected target cells was statistically significant, we utilized the
Student t test to compare mean IFN- spots generated by CD8 T cells in
response to JA2.1 cells pulsed with peptide (relevant versus irrelevant) and those
infected with an rVV construct (relevant versus irrelevant). To determine
whether immunization with a given epitope led to viral titer reduction in the
spleen following i.p. challenge, we used the Student t test.
RESULTS
Identification of candidate HLA-A*0201-restricted epitopes
that are cross-reactive among arenavirus family members.
The primary goal of our study was to determine whether highly
conserved, cross-reactive human CD8 T-cell epitopes exist
among pathogenic arenaviruses and, if so, to determine
whether they could be successfully utilized as multivalent vac-
cine determinants to provide cross-protection against heter-
ologous arenavirus infection. In previous studies, we had
identified HLA-A*0201-restricted epitopes derived from
Old World arenaviruses LCMV (GPC447-455) and LASV
(GPC42-50 and GPC60-68) that were protective against viral
challenge following peptide immunization of HLA-A*0201
mice (6, 8). To evaluate whether these protective epitope se-
quences would be conserved among diverse arenaviruses and
therefore serve as candidates for multivalent vaccination, we
conducted sequence alignments comparing each linear epitope
sequence to its corresponding region in other Old World and
New World arenavirus family members. None of the epitopes
examined shared 100% sequence homology with other arena-
viruses (Table 1 and data not shown). We did, however, iden-
tify a panel of peptide sequences corresponding to LCMV
GPC447-455 that differed from this epitope by 1 to 4 amino acids
and contained permissive HLA-A2 supertype B- and F-pocket
anchor residues at positions 2 and 9, respectively (Table 1).
The highest degree of sequence conservation was found be-
tween LCMV GPC447-455 and LASV GPC441-449, where a sin-
gle, conservative Val-to-Ile substitution was observed at posi-
tion 3. Greater diversity in primary sequence (range, 2 to 4
amino acid substitutions) was found between LCMV GPC447-455
and the corresponding peptides found in the New World
arenaviruses.
Next, to examine the breadth of HLA coverage afforded by
this panel of arenavirus peptides, we measured the binding
affinities of these peptides to common HLA-A2 supertype
alleles (HLA-A*0201, -A*0202, -A*0203, -A*0206, and
-A*6802). To determine binding affinity, each peptide was
mixed with a radioactively labeled control peptide and coincu-
bated with purified MHC as described in Materials and Meth-
ods. High-affinity binding (defined here as a 50% inhibitory
concentration [IC50] less than or equal to 100 nM) to 3 or more
HLA-A2 supertype alleles was observed for each peptide (Ta-
ble 1). Binding affinity to purified HLA-A*0201 ranged from
10 nM for PICV GPC455-463 to 326 nM for JUNV GPC429-437/
MACV GPC429-437. These data indicate that this set of arena-
virus peptides has the potential to provide broad population
coverage.
CD8 T cells from HLA-A*0201 mice infected with LCMV
cross-reactively kill APC pulsed with Old World and New
World arenavirus peptides. Next, we wished to determine
whether the candidate peptides we had identified from patho-
genic arenaviruses (LASV GPC441-449, LCMV GPC447-455,
MACV GPC444-452, JUNV GPC429-437, GTOV GPC427-435,
and WWAV GPC428-436) would be cross-reactively recognized
by CD8 T cells in the context of an arenavirus infection. To
do so, we infected HLA-A*0201 mice with 2  105 PFU of
LCMV strain Armstrong by i.p. inoculation and 7 days later
screened these animals for in vivo CTL killing of syngeneic,
CFSE-labeled target cells that had been pulsed with an arena-
virus peptide (CFSEhi) or an irrelevant peptide (CFSElo). We
observed significant levels of specific killing against antigen-
presenting cells (APC) pulsed with the homologous LCMV
peptide GPC447-455 (range, 70 to 95%) as well as targets pulsed
with heterologous arenavirus peptides, including LASV
GPC441-449 (range, 96 to 97%), GTOV GPC427-435 (range, 60
TABLE 1. Summary of candidate cross-reactive epitopes from pathogenic arenaviruses, including sequence comparison and binding affinity to
common HLA-A2 supertype alleles
Virus Peptidepositiona
Peptide sequence at positionb: Binding affinity (IC50 
nM)
1 2 3 4 5 6 7 8 9 A*0201 A*0202 A*0203 A*0206 A*6802
LASV GPC441-449 Y L I S I F L H L 14 173 11 10 6,657
LCMV GPC447-455 Y L V S I F L H L 35 7 47 70 739
MACV GPC444-452 F T A S L F L H L 326 5 13 4 1JUNV GPC429-437
GTOV GPC427-435 G T T S L F L H L 49 57 750 5 5
WWAV GPC428-436 Y V S S I F L H L 14 1 10 15 1
PICV GPC455-463 Y T I T V F L H L 10 128 14,759 7 5
a Peptide position within each arenavirus GPC open reading frame.
b Italicized numbers represent the B- and F-pocket anchor residues at positions 2 and 9, respectively. Bold residues indicate homology with LCMV GPC447-455 or
LASV GPC441-449.
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to 86%), and WWAV GPC428-436 (range, 52 to 73%) (Fig. 1).
The JUNV GPC429-437/MACV GPC429-437 peptide, which had
the weakest HLA-A*0201 binding affinity (326 nM) (Table 1),
did not induce significant killing. Collectively, the results of this
experiment demonstrate that most of the peptides in the set
have potential diagnostic value as they can be recognized fol-
lowing infection with a heterologous arenavirus. Cross-reactive
killing of APC pulsed with PICV GPC455-463 was not assessed
in this experiment, as PICV has not been shown to cause
naturally occurring human disease (12). While laboratory-ac-
quired infections have been documented, they have not been
linked with any definite illness.
Immunization of HLA-A*0201 mice with arenavirus
epitopes induces cross-reactive CD8 T-cell responses to het-
erologous peptides. To determine whether the identified pep-
tides could induce cross-reactive CD8 T-cell responses in vivo
and thus be used as vaccine candidates, groups of HLA-
A*0201 mice were immunized with individual candidate
peptides via s.c. inoculation as described in Materials and
Methods. CD8 T cells were isolated at 11 to 14 days postim-
munization and exposed to JA2.1 target cells that had been
pulsed with decreasing serial 20-fold doses (range, 1  10	5 to
6.25  10	11 M) of each candidate peptide in an ex vivo IFN-
ELISPOT assay. A given dose was considered immunogenic if
it induced IFN- spot formation that was significantly higher
than the observed response to an identical dose of an irrele-
vant, HLA-A*0201-restricted peptide.
Following immunization, high-avidity CD8 T-cell re-
sponses (endpoint reactivity range, 1  10	9 to 6.25  10	11
M) were observed against each immunizing peptide, with the
exception of JUNV GPC429-437/MACV GPC429-437 (endpoint,
1  10	5 M) (Fig. 2A to F). Binding affinity for HLA-A*0201
correlated with CD8 T-cell avidity as immunizing peptides
that bound HLA-A*0201 with IC50s of 10 to 49 nM induced
high-avidity CD8 T-cell responses (endpoint, 1  10	9 M or
less), while the JUNV GPC429-437/MACV GPC429-437 peptide
that bound at 326 nM led to a low-avidity response (endpoint,
1  10	5 M).
Variable patterns of CD8 T-cell cross-reactivity were ob-
served following peptide immunization. For example, follow-
ing immunization with the Old World peptides LASV GPC441-449
and LCMV GPC447-455, nearly identical high-avidity CD8

T-cell responses to both the immunizing peptide and the cor-
responding heterologous Old World peptide were observed in
each case (Fig. 2A and B). Detectable responses were also
observed against a subset of the New World peptides in these
animals, including PICV GPC455-463, JUNV GPC429-437/MACV
GPC429-437, GTOV GPC427-435, and WWAV GPC428-436 follow-
ing LCMV GPC447-455 immunization or PICV GPC455-463
and MACV GPC444-452/JUNV GPC429-437 following LASV
GPC441-449 immunization. With that said, responses against the
New World peptides were of low avidity (range, 1  10	5 to 2.5 
10	8) and relatively low frequency.
Following immunization with the New World peptides
GTOV GPC427-435, WWAV GPC428-436, and PICV GPC455-463,
high-avidity CD8 T-cell responses were observed against a
subset of the New World peptides in each case while cross-
reactive responses to the Old World peptides, while detectable,
were of lower avidity and frequency (Fig. 2D to F). For exam-
ple, following immunization with GTOV GPC427-435, the
MACV GPC444-452/JUNV GPC429-437 and WWAV GPC428-436
peptides were recognized by CD8 T-cell responses with fre-
quencies and avidities similar to those seen against the immu-
nizing GTOV GPC427-435 peptide, while PICV GPC455-463 was
not recognized (Fig. 2D). The LASV GPC441-449 and LCMV
GPC447-455 peptides were recognized in these animals, but the
responses to these peptides were of lower magnitude and avid-
ity (endpoint reactivity, 2.5  10	8 M). WWAV GPC428-436-
primed CD8 T cells recognized each of the heterologous
peptides screened, but IFN- spot formation was 10-fold
lower than that of the immunizing peptide, and only the
GTOV GPC427-435 and PICV GPC455-463 peptides induced
significant responses at 1  10	9 M (Fig. 2E). Finally, follow-
ing PICV GPC455-463 immunization, heterologous peptides in-
duced low-avidity CD8 T-cell responses (endpoint range, 1 
10	5 to 2.5  10	8 M) of relatively low magnitude.
Cross-reactive CD8 T-cell recognition of naturally pro-
cessed peptides from native LASV GPC or LCMV GPC ex-
pressed in HLA-A*0201-restricted human APC. Because the
strongest cross-reactive CD8 T-cell responses were observed
among the Old World epitopes LASV GPC441-449 and LCMV
GPC447-455 following peptide immunization (Fig. 2), we fo-
cused on addressing the suitability of these two peptides as
vaccine candidates for the remainder of the study. One impor-
tant consideration was whether these peptides could be pro-
/
FIG. 1. Cross-reactive in vivo killing of peptide-pulsed target cells
in LCMV-infected HLA-A*0201 mice. HLA-A*0201 mice were inoc-
ulated by i.p. injection with 2  105 PFU of LCMV strain Armstrong
53b or were uninfected (control). Seven days later, CFSE-labeled
target cells (CFSEhi, pulsed with LASV GPC441-449, LCMV GPC447-455,
JUNV GPC429-437/MACV GPC444-452, GTOV GPC427-435, or WWAV
GPC428-436; CFSE
lo, pulsed with an irrelevant peptide) were delivered
to recipient mice by i.v. injection. After 18 h, CFSE-labeled cells were
recovered from the spleens of recipient mice and enumerated. Num-
bers represent the percentage of CFSEhi peptide-pulsed target cells
that were killed in infected animals compared to that in uninfected
control animals.
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cessed from their native viral antigens by human APC and
presented to CD8 T cells that had been primed with either
LASV GPC441-449 or LCMV GPC447-455. To express native
arenavirus GPC proteins within human APC, we infected
JA2.1 cells with rVV encoding the full-length LASV GPC
(vvLASV-GPC) or LCMV GPC (vvLCMV-GPC) (see Mate-
rials and Methods). To assess epitope processing and CD8
T-cell recognition of presented peptides, splenic CD8 T cells
from HLA-A*0201 mice that had previously been immunized
with LASV GPC441-449 or LCMV GPC447-455 were screened
for IFN- secretion in response to JA2.1 cells that had been
either pulsed with peptide (irrelevant A*0201-restricted pep-
tide, LASV GPC441-449, or LCMV GPC447-455) or infected with
VV (vvWT, vvLASV-GPC, or vvLCMV-GPC) (Fig. 3). Both
LASV GPC441-449-primed (Fig. 3A) and LCMV GPC447-455-
primed (Fig. 3B) CD8 T cells generated significant levels of
IFN- spots following exposure to JA2.1 cells that expressed
the homologous and heterologous GPC proteins, respectively,
confirming that cross-reactive recognition of naturally pro-
cessed peptides occurs in the context of human APC.
Cross-reactive in vivo CTL killing following peptide immu-
nization. We next wished to evaluate whether peptide immu-
nization of HLA-A*0201 mice with LCMV GPC447-455 or
LASV GPC441-449 would induce CD8
 T cells capable of cross-
reactively killing peptide-pulsed target cells in vivo. Mice were
immunized with peptide (LCMV GPC447-455 or LASV
FIG. 2. Immunization of HLA-A*0201 mice with arenavirus epitopes induces cross-reactive CD8 T-cell responses to heterologous peptides.
HLA-A*0201 mice were immunized s.c. with either LASV GPC441-449 (A), LCMV GPC447-455 (B), JUNV GPC429-437/MACV GPC444-452 (C),
GTOV GPC427-435 (D), WWAV GPC428-436 (E), or PICV GPC455-463 (F). Splenic CD8
 T cells were isolated 11 to 14 days later and exposed to
JA2.1 cells that had been pulsed with serial 20-fold gradient doses (range, 1  10	5 to 6.25  10	11 M) of either the immunizing peptide or the
corresponding heterologous peptides in an ex vivo IFN- ELISPOT assay. Peptides were considered immunogenic if they induced IFN- spot
formation that was significant compared to that on JA2.1 target cells that had been pulsed with an irrelevant HLA-A*0201-restricted peptide. In
each graph, the green square/line represents the immunizing peptide, the black triangle/line represents the irrelevant HLA-A*0201-restricted
peptide, and the horizontal dashed line indicates the maximal level of IFN- spot formation in response to the irrelevant HLA-A*0201 peptide.
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GPC441-449) or adjuvant alone (control), and 10 days later,
CFSE-labeled target cells that had been pulsed with either
LCMV GPC447-455 or LASV GPC441-449 (CFSE
hi) were com-
bined with equal numbers of target cells pulsed with an HLA-
A*0201-restricted, irrelevant peptide (CFSElo) and delivered
via i.v. injection. The results of this experiment are displayed in
Fig. 4. Each of the peptides was able to induce specific killing
of target cells pulsed with either the immunizing peptide or the
corresponding heterologous peptide in each case. Following
immunization with LCMV GPC447-455, the magnitude of kill-
ing against the immunizing peptide ranged from 16.0 to 46.0%
while cross-reactive killing against targets pulsed with LASV
GPC441-449 ranged from 30.3 to 48.0%. Following immuniza-
tion with LASV GPC441-449, specific killing against the immu-
nizing peptide ranged from 23.8 to 58.7% while cross-reactive
killing against targets pulsed with LCMV GPC447-455 ranged
from 34.0 to 39.4%. Thus, peptide immunization could elicit
CD8 T cells capable of cross-reactive killing.
HLA-A*0201 mice immunized with LASV GPC441-449 are
protected from heterologous LCMV challenge. Having previ-
ously demonstrated that immunization of HLA-A*0201 mice
with LCMV GPC447-455 could provide protection against
LCMV challenge (8), we wished to determine whether immu-
nization with LASV GPC441-449 could provide cross-protection
against a heterologous LCMV challenge. Figure 5A outlines
the logistics of the challenge experiment. Groups of HLA-
A*0201 mice (n  5 per group) were immunized with LASV
GPC441-449, LCMV GPC447-455, or adjuvant alone (control
group). LCMV GPC447-455 served as a positive control for this
experiment. On day 14 postimmunization, mice were chal-
lenged with 2  105 PFU of LCMV via i.p. inoculation. Spleens
were harvested from each mouse on day 4 postchallenge and
screened for LCMV titer (Fig. 5B) and epitope-specific CD8
T cells (Fig. 5C). Each of the control animals (adjuvant alone)
displayed evidence of high-titer LCMV replication following
challenge (Fig. 5B). As expected, prior immunization with
LCMV GPC447-455 led to a significant decrease (85%; P 
0.004) in mean viral titer compared to that in control animals.
We also observed a significant reduction in mean viral titer
FIG. 3. CD8 T-cell recognition of naturally processed peptides
from native LASV GPC or LCMV GPC expressed in HLA-A*0201-
restricted human APC. HLA-A*0201 mice were immunized with ei-
ther LASV GPC441-449 (A) or LCMV GPC447-445 (B) as indicated
above each graph. Splenic CD8 T cells were isolated 11 to 14 days
later and exposed to JA2.1 cells that had been pulsed with peptide
(LASV GPC441-449, LCMV GPC447-445, or irrelevant peptide) or in-
fected with either wild-type VV (vvWT) or an rVV that expresses the
native LASV GPC (vvLASV-GPC) or LCMV GPC (vvLCMV-GPC)
in an ex vivo IFN- ELISPOT assay. Peptides or rVVs were considered
immunogenic if they induced IFN- spot formation that was significant
compared to that on JA2.1 target cells that had been pulsed with an
irrelevant HLA-A*0201-restricted peptide or infected with vvWT. Im-
munogenic responses are denoted by an asterisk.
FIG. 4. Heterologous in vivo killing of LASV GPC441-449- or
LCMV GPC447-455-pulsed target cells in peptide-immunized HLA-
A*0201 mice. HLA-A*0201 mice were immunized with LASV
GPC441-449, LCMV GPC447-455, or adjuvant alone (control). Ten days
later, CFSE-labeled target cells (CFSEhi, pulsed with LCMV GPC447-455
or LASV GPC441-449; CFSE
lo, pulsed with an irrelevant peptide) were
delivered to recipient mice by i.v. injection. After 18 h, CFSE-labeled
cells were recovered from the spleens of recipient mice and enumer-
ated. Numbers represent the percentage of CFSEhi peptide-pulsed
target cells that were killed in arenavirus peptide-immunized animals
compared to that in control animals.
9952 BOTTEN ET AL. J. VIROL.
following immunization with the heterologous peptide LASV
GPC441-449 (92% reduction; P  0.005).
Protection correlates with expansion of epitope-specific
CD8 T cells. We next wished to determine whether an ex-
pansion of CD8 T cells specific for LCMV GPC447-455 and/or
LASV GPC441-449 would correlate with the protection ob-
served in Fig. 5B. To do so, for each challenge group (LCMV
GPC447-455-immunized, LASV GPC441-449-immunized, or ad-
juvant only-immunized mice), we measured the frequency of
splenic CD8 T cells specific for LCMV GPC447-455, LASV
GPC441-449, or an irrelevant HLA-A*0201-restricted peptide in
an IFN- ELISPOT assay. Four days after viral challenge, mice that
had previously been immunized with LCMV GPC447-455 or LASV
GPC441-449 showed a clear expansion of CD8
 T cells that
were specific for either of these peptides in each case (Fig. 5C).
In both of these peptide-immunized groups, approximately
equal numbers of IFN- spots were formed against LCMV
GPC447-455 and LASV GPC441-449.
DISCUSSION
Arenaviruses are a family of rodent-borne viruses that cause
significant human disease throughout the world. Currently, no
FDA-approved vaccines exist for the eight antigenically diverse
species of arenavirus that are known to cause human disease.
Therefore, it is a priority to develop vaccines for the preven-
tion of human disease caused by these pathogens. Considering
the large number of arenavirus species that need to be tar-
geted, it would be highly desirable to develop multivalent vac-
cines that could provide cross-protection against multiple
arenavirus species. Over the past several years, our research
team has focused on the development of such multivalent
vaccines. Our approach has been to capitalize on the known
importance of the cellular immune response for providing pro-
tective immunity and accordingly to develop epitope-based
vaccines capable of inducing protective CD8 T-cell responses
specific to multiple arenaviruses (7). We have tested two strat-
egies to induce multivalent protection: inclusion of protective
HLA-restricted epitopes corresponding to each of several tar-
geted arenaviruses in a single vaccine (28) and, alternatively, to
reduce the complexity of the vaccine, inclusion of highly con-
served, cross-reactive epitopes, each of which has the capacity
to induce cross-protection against multiple arenaviruses. In the
present study, we have formally demonstrated that highly con-
served, cross-reactive human CD8 T-cell epitopes exist
among pathogenic arenaviruses and that they can be success-
fully utilized as multivalent vaccine determinants to provide
cross-protection against heterologous arenavirus infection.
Our finding of heterologous immunity following immuniza-
tion with an HLA-restricted epitope extends observations ini-
tially made by Peters et al. when they demonstrated, in a
guinea pig model of arenavirus infection, that heterologous
immunity could be induced between several species of Old
World arenaviruses (39). In that study, prior infection of
guinea pigs with LCMV or another Old World arenavirus,
Mopeia virus (MOPV), provided complete protection against a
subsequent challenge with a lethal dose of LASV. Likewise,
previous infection with LASV provided protection against sub-
sequent challenge with LCMV. In each case, nAbs specific for
the heterologous challenge viruses were not detectable at the
time of challenge or viral clearance. Furthermore, adoptive
transfer experiments formally demonstrated that splenocytes,
but not plasma, were responsible for this heterologous immu-
nity. Finally, lymphocytes from these animals were able to kill
syngeneic target cells that had been infected with either the
homologous priming virus or the heterologous challenge virus.
Similarly, heterologous immunity has also been observed in
nonhuman primate models of arenavirus infection. For exam-
ple, previous infection of nonhuman primates with MOPV
provided heterologous protection against a subsequent chal-
lenge with LASV despite an absence of nAb to the heterolo-
gous challenge virus (39). While the absence of nAb in the
above-mentioned studies strongly suggests that cell-mediated
immunity is responsible for providing protective heterologous
immunity, it was not formally shown. More recently, however,
Rodriguez-Carreno et al. demonstrated that immunization of
BALB/c mice with a DNA vaccine encoding a CD8 T-cell
epitope derived from LASV NP was sufficient to confer het-
erologous protection against LCMV challenge (43). Likewise,
in the present study, we show for the first time that an HLA-
restricted epitope derived from LASV can induce heterolo-
gous protection against LCMV challenge in HLA transgenic
mice. These findings confirm that, regardless of the host
species’ MHC background, CD8 T-cell responses directed
FIG. 5. Peptide immunization of HLA-A*0201 mice with LASV
GPC441-449 provides heterologous protection against a subsequent
challenge with LCMV. The logistics of the challenge experiment are
outlined in panel A. HLA-A*0201 mice (n  5 per group) were
immunized with adjuvant alone (control), LASV GPC441-449, or
LCMV GPC447-455 as described in Materials and Methods. On day 14
(d14) postimmunization, mice were inoculated i.p. with 2  105 PFU
of LCMV strain Armstrong 53b. Spleens were harvested on day 4
postchallenge for determination of viral titer (B) and enumeration of
epitope-specific CD8 T cells (C). Mean viral titers from each peptide-
immunized group were compared to those of the control group by
using the Student t test to determine whether differences were signif-
icant. Significant reductions in viral titer are indicated (*, P  0.005;
**, P  0.004). In panel C, splenic CD8
 T cells from each group of
animals were exposed to LCMV GPC447-455, LASV GPC441-449, or an
irrelevant HLA-A*0201-restricted peptide as a control in an ex vivo
IFN- ELISPOT assay. SE, standard error.
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against an epitope that is conserved among arenaviruses is
sufficient to provide robust heterologous immunity to antigeni-
cally diverse arenavirus species.
One potential concern in this study was whether our ap-
proach to multivalent vaccination, namely, immunization with
a CD8 T-cell epitope derived from LCMV or LASV, would
lead to “original antigenic sin” with regard to the resulting
CD8 T-cell response to the heterologous peptide in each case
(either the LASV or LCMV peptide, respectively). The
epitopes used as vaccine determinants, LCMV GPC447-445 and
LASV GPC441-449, differ from one another by a single, conser-
vative amino acid substitution at position 3 (Table 1). Klener-
man and Zinkernagel had previously demonstrated that orig-
inal antigenic sin can occur with CD8 T-cell responses in the
murine model of LCMV infection (26). Specifically, they found
that C57BL/6 mice primed with LCMV strain WE generated a
CD8 T-cell response to GPC33-41 but that upon secondary
challenge with a WE variant containing a mutant GPC33-41
epitope (differing from the wild type [WT] by a single, conser-
vative amino acid substitution at position 3), the CD8 T-cell
response was directed against the WT epitope and not the
variant epitope. Inversely, a primary infection with the WE
variant followed by a secondary challenge with WT WE led to
CD8 T-cell responses that were equal between the WT and
mutant epitopes. This same phenomenon was also observed
for the H-2d-restricted peptide, NP118-126. Based on these ob-
servations, Klenerman and Zinkernagel concluded that the
CD8 T-cell response was determined by the original peptide
presented and that cross-reactivity was asymmetrical (26).
Therefore, the order in which epitopes are seen can potentially
determine the breadth of the response to heterologous pep-
tides that share high levels of amino acid sequence identity. In
our study, we clearly show that original antigenic sin does not
occur with respect to the peptides LCMV GPC447-445 and LASV
GPC441-449 as immunization with either peptide leads to virtu-
ally identical CD8 T-cell responses to both the immunizing
and heterologous peptides in each case (Fig. 2 to 4). Likewise,
in the challenge assay, previous immunization with LASV
GPC441-449 followed by heterologous LCMV challenge led to
equivalent CD8 T-cell responses against LCMV GPC447-445
and LASV GPC441-449 (Fig. 5). With that said, immunization
of HLA-A*0201 mice with certain New World peptides in our
set did not always result in equal CD8 T-cell responses to
both the immunizing peptide and heterologous peptide(s). For
example, while immunization with GTOV GPC427-435 led to a
CD8 T-cell response that was similar in both magnitude and
avidity to those of both GTOV GPC427-435 and WWAV
GPC428-436, immunization with WWAV GPC428-436 resulted in
a response where the magnitude of CD8 T cells recognizing
WWAV GPC428-436 was approximately 10-fold higher than the
number of CD8 T cells recognizing GTOV GPC427-435.
Therefore, it is important to verify, for each cohort of cross-
reactive epitopes, that original antigenic sin is not impacting
immunity to the targeted, heterologous epitopes.
In the present study, we focused on one particular set of
epitopes that are conserved among pathogenic arenaviruses to
provide proof of principle that such HLA class I-restricted
epitopes exist in nature and that they can be used to induce
cross-protective immunity to heterologous arenavirus chal-
lenge. However, in our ongoing efforts to identify HLA-re-
stricted epitopes from pathogenic arenaviruses, we have found
additional HLA-A2 and HLA-A3 supertype-restricted
epitopes that are either (i) completely homologous in primary
sequence among one or more pathogenic arenaviruses (n  1)
or (ii) highly conserved (differing in primary sequence from
one virus to another by 1 to 2 amino acid residues) and cross-
reactive among several pathogenic arenaviruses (n  4) (28).
In addition to our findings, ter Meulen et al. have shown that
CD4 T cells from patients previously exposed to LASV are
able to cross-reactively recognize epitopes derived from
MOPV (51). There are also many examples of HLA-restricted
epitopes that are conserved/cross-reactive among multiple spe-
cies of viruses, including viruses within the Hantavirus genus
(24, 52) and Flaviviridae family (37, 38, 55). Therefore, our
strategy for multivalent vaccination may be applicable beyond
the arenavirus family. Indeed, members of our team have re-
cently shown that HLA-restricted CD4 T-cell epitopes that
are conserved among pathogenic influenza virus strains exist
and that they too are protective (2).
In addition to having utility as vaccine determinants, the
cross-reactive epitopes identified in this study also have value
as diagnostic reagents. As we demonstrate in Fig. 1, following
an experimental infection with LCMV in HLA transgenic
mice, peptides derived not only from the corresponding Old
World virus LASV but also from the New World viruses
GTOV and WWAV are recognized via an in vivo cytotoxicity
assay. Sets of peptides such as this would be valuable tools for
monitoring at-risk populations for arenavirus exposure, inves-
tigating the role of T cells in arenavirus pathogenesis in hu-
mans, and evaluating the capacity of new candidate vaccines to
effectively induce cell-mediated immunity. One important con-
sideration regarding our study is the fact that there is an in-
complete overlap in the epitopes recognized by HLA trans-
genic mice and humans (27). Therefore, it will be important to
verify that the epitopes identified in the current study can
indeed be recognized in HLA-A*0201-restricted humans fol-
lowing exposure to pathogenic arenaviruses.
In conclusion, we have demonstrated that HLA-restricted,
cross-reactive epitopes exist among pathogenic arenaviruses
and that individual epitopes can be utilized as effective vaccine
determinants for multiple pathogenic arenaviruses. Because
the epitopes in this study are HLA-A2 supertype restricted,
they are capable of providing broad population coverage
(43% of the population, regardless of ethnicity) (45). Inclu-
sion of cross-protective epitopes such as these in multivalent
vaccine formulations will allow for a reduction in the complex-
ity of the resulting vaccine. While the current study provides
proof of concept for the proposed multivalent vaccination
strategy, future studies to advance this approach will focus on
the identification of other cross-protective epitopes that cor-
respond to additional HLA supertype families and arenavi-
ruses to increase coverage of both HLA backgrounds and
pathogenic arenavirus species.
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